Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on developmental toxicity

Description of key information
NOAEL: > 3000 mg/kg bw (Bailey,2010)
Effect on developmental toxicity: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
3 000 mg/kg bw/day
Species:
mouse
Additional information

In an developmental toxicity study (similar to OECD 414) with 1-ethyl-3-methylimidazolium chloride (C2mim Cl) 25 female CD1- mice were exposed at concentration of 1000, 2000 and 3000 mg/kg day. The mated mice were orally dosed from gestation day (GD) 6 -16. The Dams were scrifieced on GD 17, and their litters were examined for adverse effects. The numbers of implantations and the percentages of resorbed or dead fetuses did not differ significantly among treatment groups. There was no effect on fetal weight among the exposed fetuses. No gross malformations were observed in fetuses. There was an increased litter incidence of supernumerary ribs, but not statisically significant. The study did not find significant differences in the number of implantations, vialble fetuses or resorbed/dead fetuses among the treatment groups. There were no morphological aberrations.

The present study conducted with pregnant mice gavaged with imidazolium-based ionic liquids (1-ethyl-3-methylimidazolium chloride, 1-Butyl.-3-methylimidazolium chloride and 1-decyl-3-methylimidazolium chloride) supports the contention that toxicc effects of the ILs increase with increasing alkyl chain length. That relationship was anifested by maternal morbidity and mortality and by effects on fetal weight. The same may be true of malformations, as they were seen only in fetuses from dams exposed to the two longer chain ILs, although differences in dosage levels among the three test sompounds mae direct comparison more difficult. (Bailey, 2010)

There are further studies performed to assess the influence of the anion on the developmental toxicity of two repesentative imidazolium-ILs, 1-ethyl-3-methylimidazolium chloride ([emim]Cl) and 1-ethyl-3-methylimidazolium acetate ([emin]Ac)-treated . Mated CD-1 mice were orally dosed with 2500 mg/kg/day form gestation days (GD) 6 -16. Dams were sacrificed on GD 17 an there littes were examined for advere effects. A significant increase in maternal morbidity was observed in the [emin]Ac-treated group compared to controls, but no statistically significant decrease in fetal weight or increase in fetal malformations was associated with either IL treatment. The percentage of resorbed or dead fetuses was increased in both treated groups compared to controls, but the differences were not statistically significant. Anion composition influenced the maternal toxicity of a short-chain imidazolium-based ionic liquid; however, there were no anion-associated differences in adverse effects on the developing offspring. (Herring B.J., Birth Defects Research; Poster Abstracts (Part A) 88: p.392 (2010) and 91: p.376 (2011)).


Justification for selection of Effect on developmental toxicity: via oral route:
only available study

Justification for classification or non-classification

Based on the results, the test item is no subject to classification and labelling according to Regulation (EC) No 1272/2008 (CLP).

Additional information